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Abstract 
Cognitive decline is one of the most frequent and disabling non-motor features of 
Parkinson´s disease. Around 30% of patients with Parkinson’s disease experience mild 
cognitive impairment, a well-established risk factor for the development of dementia. 
However, mild cognitive impairment in patients with Parkinson’s disease is a 
heterogeneous entity that involves different types and extents of cognitive deficits. Since 
it is not currently known which type of mild cognitive impairment confers a higher risk of 
progression to dementia, it would be useful to define biomarkers that could identify these 
patients to better study disease progression and possible interventions. In this sense, the 
identification among patients with Parkinson’s disease and mild cognitive impairment of 
biomarkers associated with dementia would allow the early detection of this process. This 
review summarizes studies from the last 25 years that have assessed potential biomarkers 
of dementia and mild cognitive impairment in Parkinson’s disease patients. Despite the 
potential importance, no biomarker has as yet been validated. However, features such as 
low levels of epidermal and insulin-like growth factors or uric acid in plasma/serum and 
of Aß in CSF, reduction of cerebral cholinergic innervation and metabolism measured by 
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PET mainly in posterior areas, and hippocampal atrophy in MRI might be indicative of 
dementia or of subgroups of patients with distinct subtypes of cognitive deficits with a 
distinct risk of dementia. Therefore, longitudinal studies combining the existing 
techniques and new approaches will be needed to identify patients at higher risk of 
dementia. 
 
 
INTRODUCTION 
It is only in recent decades that cognitive impairment has become recognized as a relevant 
clinical manifestation of PD, the prevalence of dementia reaching 80% in long-term 
patients.
1, 2
 Mild cognitive impairment (MCI) is also highly prevalent in PD (PD-MCI: 
mean 26.7%; range 18.9%–38.2%)3 and it is known to be a risk factor for dementia 
(PDD).
3-7
 PD-MCI is defined as cognitive decline that is not normal for the age and 
educational level of the patient but that is not associated with impaired functional 
activity.
8
 However, PD-MCI is a heterogeneous entity that covers several forms of 
cognitive impairment in function of the number and type of cognitive domains affected.
8
 
It is not currently known which types of PD-MCI confer a higher risk of progression to 
dementia. In this sense, useful biomarkers are needed that can predict future outcome or 
that are useful to longitudinally track the underlying disease pathology in an objective 
way. Thus, there is increasing interest in the search for biomarkers that could aid in the 
identification of such PD-MCI patients. The assessment of biomarkers already associated 
with PDD in PD-MCI patients is one interesting approach to define subtypes of MCI that 
share biological features with dementia. In this review, we summarize the data currently 
available regarding the biological markers of dementia and MCI in PD. 
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LITERATURE SEARCHING STRATEGY 
The literature in Medline (PubMed) from 1990 to July 2015 was reviewed using the free 
search terms Parkinson’s disease AND (dementia OR mild cognitive impairment), 
combined with the following terms/sets of terms: cerebrospinal fluid; blood OR plasma; 
genes OR DNA OR polymorphism; magnetic resonance imaging; PET; SPECT; 
electroencephalogram; magnetoencephalography; evoked potentials. The search was 
limited to articles in English and the reference lists were searched for additional 
publications. Since the concept of PD-MCI was introduced only a few years ago and the 
diagnostic criteria (MDS Task Force)
8
 were only recently adopted, some studies only 
distinguished between PDD and non-demented PD patients (PDND), while in others 
cognitively normal PD patients (PDCN) and PD-MCI were considered. Notably, several 
studies did not specify whether PD patients were PDCN or PDND, referring to them just 
as PD. In this review we will maintain the nomenclature used in the original papers. In 
addition to the studies in which a diagnosis of PDD or PD-MCI was indicated, those 
studying correlations between biomarkers and cognitive performance have been 
considered. Studies in which cognitive diagnosis was only based on subjective medical 
assessment, without any formal neuropsychological evaluation, case reports and case 
series were excluded. 
 
CEREBROSPINAL FLUID 
The presence of Lewy bodies (LB), amyloid plaques and neurofibrillary tangles in the 
neocortex and limbic system is associated with dementia
9-13
 and MCI
14, 15
 in PD. Hence, 
the levels of amyloid-ß (Aß), tau protein and α-synuclein have been studied in the 
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cerebrospinal fluid (CSF) of PD patients (Table 1). In most studies, there was less Aß in 
PDD than in healthy controls
16-20
 and PDND
16, 18, 19
 patients, and lower levels of Aß were 
associated with progression to dementia in PDND patients
21
 and a deterioration in 
attention,
22
 executive function,
22, 23
 memory
22, 23
 and global cognition.
24
 By contrast, the 
data for total (t-tau) and phosphorylated tau (p-tau) are less consistent, with increased
16, 18, 
25, 26
 or unchanged levels
17, 27-30
 in PDD patients. In PD-MCI patients, there was less
17
 or 
similar
31, 32
 Aß to that in PDCN patients, while t-tau was higher
32
 or no different,
17, 31
 and 
p-tau was comparable in both.
17, 31, 32
 Interestingly, in PDND patients, low levels of Aß
24, 
25, 33-35
 and a low Aß 1-42/total tau
24, 34
 ratio were associated with impairment in several 
cognitive domains or tests: attention and working memory,
34
 executive function,
35
 
memory,
33, 35
 and phonemic
21
 and semantic fluency.
34
 Although the total α-synuclein was 
similar in PDD and PDND patients or controls in initial studies,
26, 36
 technically more 
advanced analyses show that PDD patients have more oligomeric forms of α-synuclein,18, 
37
 and a higher total α-synuclein concentration was associated with a faster decline in 
cognitive performance in de novo patients.
38
 However, most studies fail to find any 
association between total or oligomeric α-synuclein and cognition in PDND patients.24, 35, 
39
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Table 1. Summary of the studies that evaluated CSF amyloid ß1-42 (Aß1-42), total tau (t-tau), phosphorylated tau (p-tau), total α-synuclein (t-α-syn), and oligomeric α-
synuclein (o-α-syn) as potential biomarkers for PDD or PD-MCI. 
 STUDIED BIOMARKERS  PATIENTS COGNITIVE EVALUATION / 
DIAGNOSTIC CRITERIA 
MAIN RESULTS/FINDINGS 
Aß1-
42 
T-tau P-tau T-α-
syn 
O-α-
syn 
PDND PDCN PDD PD- 
MCI 
Control   
PDD  
Jansen et al., 
1998
27 
 + +   67  48  41 MMSE / PDD if< 26 
No differences 
 
Parnetti et al., 
2008
28
 
+ + +   20  8  20 MMSE / PDD by McKeith et al., 
1996 
Maetzler et 
al., 2011
41
 
+ +    21  10  39 MMSE / PDD by DSM-IV 
Maetzler et 
al., 2012
30 
+ +    77  26  72 MMSE / PDD by DSM-IV and 
MDS Task Force 
Wennström et 
al., 2013
36
 
   +  38  22  52 MMSE / PDD by MDS Task Force 
Mollenhauer 
et al., 2006
16 
+ +    23  73  41 MMSE / PDD if< 25 PDD vs. PDND and C: ↓ Aß1-42 
PDD vs. C: ↑ t-tau 
Maetzler et 
al., 2009
20 
+     14  12   MMSE / PDD by DSM-IV PDD vs. PDND: ↓ Aß42 
Compta et al., 
2009
25 
+ +    20  20  30 MMSE, attention and working 
memory, executive, memory, 
language, visuospatial / PDD by 
DSM-IV-R and MDS Task Force 
PDD vs. PDND and C: ↑ t-tau 
PDND: ↓ Aß1-42 positively correlated with 
phonemic fluency 
 
Compta et al., 
2011
19
 
+ + +   19  19  9 MMSE / PDD by DSM-IV-R and 
MDS Task Force 
PDD vs. PDND and C: ↓ Aß1-42 
↑ t-tau and p-tau in a subgroup of PDND and PDD 
with the rs242557 A-allele of MAPT and with levels 
of Aß1-42 < 500 pg/mL 
 7 
Hall et al., 
2012
26
 
+ + + +  90  33  107 MMSE / PDD by MDS Task Force PDD vs. PDND: ↑ p-tau 
No differences in Aß1-42 or t-α-syn 
Vranová et al., 
2014
29
 
+ +    27  14  24 MMSE, attention and working 
memory, executive, memory / PDD 
by MDS Task Force 
PDD vs. PDND: ↑ t-tau/Aß1-42 index 
No differences in Aß1-42 or t-tau 
Hansson et al., 
2014
37
 
   + + 30    98 MMSE / PDD by MDS Task Force PDD vs. C: ↑ o-α-syn 
Compta et al., 
2015
18
 
+ +  + + 21  20  13 MMSE / PDD by MDS Task Force PDD vs. PDND and C: ↓ Aß1-42 and ↑ t-tau 
PDD vs. C: ↑ o-α-syn 
PD-MCI 
Beyer et al., 
2013
31
 
+ 
Aß38, 
Aß40 
+ +    73  18  MMSE, attention and working 
memory, executive, memory, 
visuospatial / PD-MCI if 
performance < 1.5 SDs below 
predicted level in ≥ 1 cognitive 
domains 
No differences 
Montine et al., 
2010
17
 
+ + +    41 11 58 150 CDR / PDD by MDS Task Force; 
PD-MCI by CDR=0.5 
PDD vs. C: ↓ Aß1-42 
PD-MCI vs. C: ↓ Aß1-42 
No differences in t-tau and p-tau 
Yu et al., 
2014
32
 
+ + +    26  36 31 MMSE, MOCA / PDD and PD-MCI 
by MDS Task Force 
PD-MCI vs. PDCN and C: ↑ t-tau 
PD-MCI: MOCA negatively correlated with t-tau 
PDND* 
Alves et al., 
2010
33 
+ 
Aß38, 
Aß40 
+ +   109    36 MMSE, attention and working 
memory, executive, memory, 
visuospatial / PDD by MDS Task 
Force 
Positive correlation between Aß42, Aß38 and Aß40 
and memory 
Siderowf et 
al., 2010
22 §
 
+ + +   45     DRS-2, memory, attention and 
working memory, initiation-
perseveration, construction, and 
conceptualization / PDD if DRS-2 < 
124 
↓ Aß1-42 associated with decline in attention, 
conceptualization, memory and 
initiation/perseveration 
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Abbreviations. Subjects: PDND, Parkinson’s disease non-demented; PDD, Parkinson’s disease with dementia; PD-MCI, Parkinson’s disease with mild cognitive 
impairment; PDCN, Parkinson’s disease cognitively normal; C, control. Cognitive assessment: MMSE, Mini Mental State Examination; MOCA, Montreal Cognitive 
Leverenz et 
al., 2011
34
 
+ +    22     MMSE, attention and working 
memory, memory, semantic fluency, 
executive, processing speed / PDD 
by consensus panel based on CDR 
Positive correlation between Aß1-42, attention and 
working memory 
Positive correlation between Aß42/t-tau and working 
memory, attention and semantic fluency 
Compta et al., 
2013
21 §
 
+     27     MMSE, executive, memory, 
language, visuospatial / PDD by 
MDS Task Force 
↓ Aß1-42 in dementia-converters 
Positive correlation between Aß1-42 and lower 
phonemic fluency 
Stewart et al., 
2014
38 §
 
   +  304     MMSE, attention and working 
memory, memory, visuospatial / 
PDD if MMSE < 23 
↑ t-α-syn at baseline predicts faster cognitive decline 
Parnetti et al., 
2014
24 §
 
+ + + + + 44    25 MMSE, MOCA Aß1-42 negative correlation with decline in MMSE 
and MOCA 
Aß1-42 and t-tau negative correlation with decline in 
MMSE 
Liu et al., 
2015
23 §
 
+ + +   403     MMSE, attention and working 
memory, executive, memory, 
visuospatial 
No association with cognitive function at baseline 
T-tau and p-tau/Aß1-42 predicted decline in memory 
and executive function 
Buddhala et 
al., 2015
39
 
+ + + +  77    30 CRD, Attention and working 
memory, executive, memory, 
language, visuospatial / PDD by 
CRD 
No association with cognition 
Stav et al., 
2015
35
 
+ + + +  31    34 Attention and working memory, 
executive, visuospatial 
Positive correlation between Aß1-42 and memory and 
response inhibition 
Backstrom et 
al., 2015
47 §
 
+ + + +  99     Attention and working memory, 
executive, memory, visuospatial / 
PDD and PD-MCI by modified 
MDS Task Force 
↓ Aß1-42 associated with progression to PDD 
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Assessment; DRS-2, Mattis Dementia Rating Scale (version 2); MDS, Movement Disorders Society; CDR, Clinical Dementia Rating; DSM, Diagnostic and Statistical 
Manual of Mental Disorders. 
 
* In these studies PDD patients were excluded according to the criteria shown. No distinction between PDCN and PD-MCI was considered in PDND patients 
§
 Longitudinal studies 
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Proteins involved in inflammatory processes, oxidative stress and neuronal viability have 
also been investigated (Supplementary table 1). More C-reactive protein (CRP) was found 
in PDD patients than in PDND and controls,
40
 and interleukin-6 (IL-6) and IL-1β were 
more elevated in PD-MCI than  in PDCN patients or controls.
32
 PD-MCI patients also had 
less interferon-γ (IFN-γ) and tumor necrosis factor α (TNF-α), and higher levels of nitric 
oxide and hydroxyl radical than controls.
32 
In addition, some of these proteins were 
associated with global cognition in PDND
40
 and PD-MCI patients.
32
 Uric acid (UA),
41
 a 
scavenger of free radicals, and cystatin C,
42
 which has anti-amyloidogenic properties, 
were also reduced in PDD and dementia with Lewy bodies (DLB) patients. Other 
proteins, such as brain derived neurotrophic factor (BDNF), eotaxin, ferritin, hypocretin 
and transthyretin
32, 34, 40, 43, 44
 did not differ between PDD and PDND or controls. Finally, 
recent proteomic analyses reveal that some proteins involved in signaling pathways, 
axonal guiding or protein folding
45, 46
 were differentially expressed in PDD and PDND 
patients. Interestingly, a profile characterized by low Aß1-42, high neurofilament light 
chain protein and high heart fatty acid-binding protein was associated with progression to 
PDD, with a relatively high diagnostic accuracy.
47
 
Despite some variability, reduced Aß in PDD patients and in PDND who progressed to 
dementia appears to be relatively consistent.
16-24
 Along with the heterogeneity in Aß 
concentrations in PD-MCI
17, 31, 32
 and the fact that low Aß correlates with specific 
cognitive deficits in PDND patients,
24, 25, 33-35
 this suggests that Aß protein might 
represent a useful biomarker to identify specific types of PD-MCI that might be at higher 
risk of suffering dementia (patients with concomitant Alzheimer’s disease [AD] or AD 
pathological changes). Although based on few studies, an increase in α-synuclein 
oligomers should also be considered.
18, 26, 36-38
 Differences in proteins related to 
 11 
inflammation,
32, 40
 oxidative stress
41
 and cell survival are also promising.
45, 46
 Proteomic 
analysis might also be considered to validate and expand current data in future studies. 
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Supplementary table 1. Summary of studies assessing CSF potential biomarkers for PDD and PD-MCI other than neuropathologic proteins and studies assessing potential 
biomarkers in plasma/serum and urine. 
 
 BIOMARKER 
PATHWAY / 
MECHANISM 
PATIENTS 
COGNITIVE EVALUATION / 
DIAGNOSTIC CRITERIA 
MAIN FINDINGS / RESULTS 
CSF      
PDD      
Kuiper et al., 
1994
43
 
Ferritin Iron carrier PDND (n=72) 
PDD (n=15) 
C (n=20) 
PDD by DSM-III-R No differences 
Compta et al., 
2009
44
 
Hypocretin Neuropeptid PDND (n=21) 
PDD (n=20)  
C (n=22) 
MMSE / PDD by DSM-IV-R and MDS 
Task Force 
No differences 
Maetzler et al., 
2010
42
 
Cystatin C Antiamyloidogenic PDND (n=52) 
PDD (n=24) 
C (n=36) 
MMSE / PDD by DSM-IV PDD vs. C: ↓ 
Maetzler et al., 
2011
41
 
Uric acid Oxidative stress PDND (n=55) 
PDD (n=20) 
C (n=76) 
MMSE / PDD by DSM-IV PDD/DLB vs. PDND: ↓ 
Maetzler et al., 
2012
30
 
Transthyretin Thyroxine and retinol 
carrier 
PDND (n=77) 
PDD (n=26) 
C (n=72) 
MMSE / PDD by DSM-IV and MDS 
Task Force 
No differences 
Jesse et al., 2012
45
 Serpin A1 Serine protease 
inhibitor 
PDND (n=24) 
PDD (n=21) 
C (n=24) 
MMSE, attention and working 
memory, executive, memory, language, 
visuospatial / PDD by DSM-IV  
Differentially sialylated isoforms of Serpin A1 
identified PDD vs. PDND with 100 % sensitivity and 
58 % specificity 
Lehnert et al., 
2012
46
 
Eotaxin, Netrin G1, non-
receptor Tyrosine-kinase 
type 13 
Miscellaneous PD (n=12) 
PDD (n=12) 
C (n=12) 
MMSE, executive, visuospatial / PDD 
by DSM-IV 
PDD vs. C: ↑ Netrin G1 and non-receptor Tyrosine-
kinase type 13 
Hall et al., 2012
26
 Neurofilament light 
chain 
Neuronal 
structure 
PDND (n=90) 
PDD (n =33) 
C (n=107) 
MMSE / PDD by MDS Task Force PDD vs. PDND: ↑ 
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Lindqvist et al., 
2013
40
 
CRP, IL-6, TNF- α, 
IP10, MIP1β, MCP1 
Inflammation/immune 
response 
PDND (n=71) 
PDD (n=16) 
C (n=33) 
MMSE / PDD by MDS Task Force PDD vs. PDND and C: ↑ CRP  
PDND: IL-6 negative correlation with MMSE. 
Wennström et al., 
2013
36
 
Neurosin Serin protease PDND (n=38) 
PDD (n=22) 
C (n=52) 
MMSE / PDD by MDS Task Force No differences 
PD-MCI      
Yu et al., 2014
32
 IL-1β, IL-6, TNF- α, 
INF-γ, PGE2 
OH, H2O2, NO 
Inflammation/immune 
response 
Oxidative stress 
PDCN (n=26) 
PD-MCI (n=36) 
C (n=31) 
MMSE, MOCA / PD-MCI by MDS 
Task Force 
PD-MCI vs. C: ↑ IL-1β and IL-6, ↓TNF-α and INF-γ. ↑ 
OH and NO. No differences in H2O2 
PD-MCI vs. PDCN: ↑ IL-6. No differences in PGE2 
PD-MCI: IL-6 negative correlation with MOCA. 
PDND      
Leverenz et al., 
2011
34
 
Brain Derived 
Neurotrophic Factor 
Neurotrophic factors PDND (n=22) MMSE, attention and working 
memory, memory, semantic fluency, 
executive, processing speed / PDD by 
consensus panel based on CDR 
Positive correlation with attention and working 
memory 
Backstrom et al., 
2015
47
 
Neurofilament light 
chain protein, heart fatty 
acid-binding protein 
Neuronal 
structure / Lipid 
metabolism 
PDND (n=99) 
Longitudinal (9 
years) 
Attention and working memory, 
executive, memory, visuospatial / PDD 
and PD-MCI by MDS Task Force 
↑ neurofilament light chain protein and heart fatty acid-
binding protein associated with progression to PDD 
PLASMA/SERUM     
PDD / PDND       
Bialecka et al., 
2012
48
 
Homocysteine (P) Cardiovascular risk PDND (n=153) 
PDD (n=64) 
C (n=254) 
MMSE, attention and working 
memory, executive, memory, language 
/ PDD by MDS Task Force 
PDD vs. PDND: ↑ 
Song et al., 2013
49
 Homocysteine (P) Cardiovascular risk PDND (n=33) 
PDD (n=28) 
C (n=48) 
MMSE, CDR / PDD by DSM-IVR PDD vs. PDND: ↑ 
Chen-Plotkin et 
al., 2011
64
 
Epidermal Growth 
Factor (P) 
Neurotrophic factors PDND (n=70) 
Longitudinal (21 
months) 
DRS-2 / PDD if ≤ 5 Positive correlation with cognitive status at baseline 
and ↓ associated with greater risk of cognitive decline 
at follow-up 
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Song et al., 2013
56
 High-sensitivity C-
reactive protein (S) 
Inflammation/immune 
response 
PDND (n=72) 
PDD (n=45) 
C (n=84) 
MMSE, CDR / PDD by DSM-IV-R  No differences 
Peterson et al., 
2013
54
 
Vitamin D (P) Neurotrophic factors PDND (n=225) 
PDD (n=61) 
MMSE, MOCA, DRS, attention and 
working memory, executive, memory, 
visuospatial / PDD by DSM-IV 
No differences. 
PDND+PDD: positive correlation with memory and 
semantic fluency 
González-
Aramburu et al., 
2014
55
 
Uric acid (S) Oxidative stress PDND (n=271) 
PDD (n=72) 
MMSE, attention and working 
memory, executive, memory, 
visuospatial / PDD by MDS Task 
Force 
No differences 
PD-MCI/ 
PDCN/PDD 
     
Mielke et al., 
2013
73
 
Ceramide and 
monohexosylceramide 
(P) 
Lipid metabolism PDCN (n=26) 
PD-MCI (n=14) 
PDD (n=12) 
C (n=5) 
MMSE, attention and working 
memory, executive / PD-MCI and PDD 
by MDS Task Force 
PDD+PD-MCI vs. PDCN: ↑ ceramide C16:0, C18:0, 
C20:0, C22:0, and C24:0 and monohexosylceramide 
C16:0, C20:0, and C24:0 species 
Rodriguez-Oroz 
et al., 2014
51
 
Homocysteine (P) Cardiovascular risk PDCN (n=37) 
PD-MCI (n=22) 
PDD (n=30) 
C (n=30) 
MMSE, attention and working 
memory, executive, memory, language 
/ MCI by Petersen et al., 1999; PDD by 
DSM-IV 
No differences 
Li et al., 2015
70
 Phospholipids (P) Lipid metabolism PDCN (n=44) 
PD-MCI (n=41) 
C (n=75) 
MOCA / PD-MCI if < 26 PD-MCI vs. PDND and C: ↑  
PDND or PD     
O'Suilleabhain et 
al., 2004
50
 
Homocysteine (P) Cardiovascular risk PDND (n=97) MMSE, attention and working 
memory, executive, memory, language, 
visuospatial 
↑ associated with worse performance in visuospatial 
and executive functions 
Hassin-Baer et al., 
2006
52
 
Homocysteine (P) Cardiovascular risk PD (n=72) 
 
MMSE, FAB, attention and working 
memory, executive, memory, language, 
visuospatial 
No association with cognitive performance 
Camicioli et al., Homocysteine (P) Cardiovascular risk PDND (n=51) MMSE, DRS, executive, visuospatial  No association with cognitive performance 
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2009
53
 C (n=50) 
Annanmaki et al. 
2008
57
* 
Uric acid (P) Oxidative stress PD (n=40) 
 
MMSE, attention and working 
memory, executive, memory, language, 
visuospatial 
Positive correlation with lower performance in several 
cognitive tests 
Moccia et al., 
2014
58
 
Uric acid (S) Oxidative stress PD (n=80) MMSE, attention and working 
memory, memory 
↓ associated with impairment of attention/memory 
Moccia et al., 
2014
59
 
Uric acid (S) Oxidative stress PD (n=69) 
Longitudinal (2 
years) 
MMSE, attention and working 
memory, memory 
↓ associated with worsening in attention/memory  
Connolly et al., 
2008
72
** 
8,12-isoprostaneF2α-VI 
(P) 
Lipid metabolism PD (n=36) 
C (n=30) 
MMSE, executive, memory No association with cognitive performance 
Sclazo et al., 
2010
61
 
IL-6 (S) Inflammation/immune 
response 
 
PDND (n=44) MMSE Negative correlation with MMSE 
Menza et al., 
2010
60
 
IL-6, TNF- α (P) Inflammation/immune 
response 
 
PDND (n=52) MMSE, attention and working 
memory, executive, memory, language 
Both markers: negative correlation with global 
cognition 
Hassin-Baer et al., 
2011
52
 
CRP (P) Inflammation/immune 
response 
 
PD (n=73) MMSE, FAB, attention and working 
memory, executive, memory, language, 
visuospatial 
No association with cognitive performance 
Pellecchia et al., 
2013
63
 
Epidermal Growth 
Factor (S) 
Neurotrophic factors PD (n=65) 
Longitudinal (2 
years) 
MMSE, attention and working 
memory, executive, memory, 
visuospatial 
Positive correlation with performance in semantic 
fluency and color naming task of Stroop at follow up 
Pelleccia et al., 
2014
65
 
Insulin-like growth 
factor-1 (S) 
Neurotrophic factors PD (n=65) 
Longitudinal (2 
years) 
MMSE, attention and working 
memory, executive, memory, 
visuospatial 
↓ associated with faster decline in memory and 
executive function 
Ma et al., 2015
66
 Insulin-like growth 
factor-1 (P) 
Neurotrophic factors PD (n=100) 
C (n=76) 
MMSE Positive correlation with MMSE score 
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Abbreviations. Biomarkers: (P), plasma; (S), serum; CRP, C reactive protein; IL-1β, Interleukin-1β; IL-6, Interleukin-6; TNF-α, Tumor necrosis factor alpha; IFN-γ, 
Interferon gamma; PGE2, Prostaglandin E2; IP10, Interferon gamma-induced protein-10; MIP1β, Macrophage inflammatory protein-1; MCP1, Monocyte chemotactic protein-
1; Hcy, Homocystein. Subjects: PDD, Parkinson’s disease with dementia; PD-MCI, Parkinson’s disease with mild cognitive impairment; PDND, Parkinson’s disease non-
demented; PDCN, Parkinson’s disease cognitively normal; C, control. Cognitive assessment: MMSE, Mini Mental State Examination; MOCA, Montreal Cognitive 
Assessment; MDS, Movement Disorders Society; FAB, Frontal Assessment Battery; DSM, Diagnostic and Statistical Manual of Mental Disorders 
 
*Low urine uric acid levels associated with worse performance on information, similarities, BD, picture completion, DS-B, rule shift cards, 10-CRT, statement verification, 
cognitive processing vigilance. 
** Urine levels not associated with cognitive performance 
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OTHER BIOLOGICAL FLUIDS: PLASMA/SERUM AND URINE  
Apart from CSF, other biological fluids represent an attractive source of biomarkers due 
to the ease of obtaining samples (Supplementary table 1). Regarding plasmatic 
homocysteine, while some studies associated higher levels with dementia and worse 
cognitive outcome,
48-50
 others failed to find any relationship with PD-MCI, dementia or 
neuropsychological performance.
51-53
 
Plasma or serum levels of proteins involved in inflammation (CRP), oxidative stress (UA) 
or neuroprotection (vitamin D, transthyretin) were no different in PDD and PDND 
patients.
30, 54-56
 However, in PDND patients, low UA concentrations was associated with a 
worse outcome in global cognition,
57, 58
 attention, and memory;
59
 high vitamin D levels 
with better semantic fluency and memory;
54
 and high concentrations of IL-6,
60, 61
 TNF-
α,60 and IFN γ-induced protein 1062 with lower cognitive scores. Importantly, low levels 
of epidermal growth factor (EGF)
63, 64
 and insulin-like growth factor (ILGF)
65
 have 
certain predictive value for the development of dementia and cognitive decline, and ILGF 
positively correlates with global cognition
66
 and executive function.
65
 Interestingly, after 
cognitive rehabilitation plasma BDNF levels increased in PD-MCI patients.
67
 
In addition to proteins, lipids have also been evaluated as abnormal lipid peroxidation 
may play a role in the pathogenesis of PD and other neurodegenerative diseases.
68, 69
 
Whereas plasma levels of phospholipids were higher in PD-MCI than in PDCN patients,
70
 
prostaglandin isomers derived from free radical peroxidation of polyunsaturated fatty 
acids
71
 (i.e. F2-isoprostanes) did not differ between PDD and PDND patients, nor were 
they associated with the severity of cognitive impairment.
72
 Lipids involved in the 
metabolism of glucosylceramide (a GBA substrate) have also been investigated, and 
interestingly, in the absence of mutations in GBA the levels of some ceramide species 
were higher in PD-MCI or PDD than in PDCN patients.
73
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Regarding urine, only UA has been studied to date and in keeping with findings in 
plasma, low UA levels are associated with poor neuropsychological performance.
57
 
In summary, the fact that cognitive outcomes are associate with neurotrophic factors and 
markers of inflammation, and that a few longitudinal studies in small cohorts with early 
PD show that EGF,
63, 64
 ILGF
65
 and UA
59
 may predict cognitive decline, suggest that 
these proteins could be useful as biomarkers of dementia in PD. The differences in some 
lipids between groups of PD patients with distinct cognitive states may also be of 
potential value.
70, 73
 These findings are in keeping with recent data linking 
neurodegeneration and aging with disturbances in lipid metabolism
74, 75
 and 
neuroinflammation.
76
 
 
GENETIC BACKGROUND 
Genes are part of our inborn biological fingerprint and although they can be useful to 
predict outcome (i.e .risk of dementia) they are not useful to track disease course (i.e. 
cognitive evolution in a patient with PD). Thus, genetic factors are better considered as 
“predictive markers” rather than true biomarkers. Genes related to the aggregated proteins 
encountered in the brain of PDD patients
9-13
 (Table 2) have been extensively pursued. The 
ε4 allele of apolipoprotein E gene (APOE) is associated with increased amyloid plaque 
load
77
 and it was found to be more prevalent in PDD than in PDND patients,
78-81
 as well 
as being associated with lower performance in memory,
82, 83
 working memory, executive 
function and semantic fluency
83
 in PDND. However, such results were not evident 
elsewhere,
31, 84-90
 this discrepancy probably being due to the significant methodological 
variability among the studies (Table 2). Most of these cross-sectional studies have been 
pooled in one meta-analysis,
91
 suggesting an over-representation of APOE ε4 carriers 
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amongst PDD patients. In addition, although not uniformly,
22, 89, 91
 longitudinal studies 
show that APOE ε492-95 and APOE ε294, 95 are associated with more rapid cognitive 
decline and a risk of PDD. In relation to the tau gene (MAPT), despite the absence of 
uniform data,
83, 88, 92
 the H1 haplotype in PD patients was found to be associated with 
dementia
96
 and with a higher risk of progression to dementia
97
 and cognitive decline
98
 in 
the most extensive cross-sectional
96
 and longitudinal studies.
97, 98
 In addition, in PDND 
patients the H1/H1 genotype was associated with poor visual and  memory outcomes,
92, 99
 
although this finding was not replicated in a larger study.
83
 Duplications, triplications
100, 
101
 and some mutations of the SNCA gene that encodes the α-synuclein protein102, 103 are 
associated with early onset dementia, although patients with idiopathic PDD and PDND 
did not show different polymorphisms of this gene.
104
 Interestingly, a recent multicenter 
study in a large cohort of PD patients, show that the APOE ε4 allele but not the MAPT 
and SNCA genes was associated with lower cognitive performance.
83 
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Table 2. Summary of genetic studies assessingAPOE, MAPT and GBA as potential biomarkers of PD-MCI 
and PDD. 
AUTHOR PATIENTS 
COGNITIVE EVALUATION / 
DIAGNOSTIC CRITERIA 
MAIN RESULTS / FINDINGS 
 
PDND PDD 
PD- 
MCI 
Cont
rols 
 
 
APOE  
CROSS-SECTIONAL 
Koller et al., 1995
84
 61 52   DRS / PDD by NINCDS 
No differences 
Parsian et al., 2002
85
 250 34  96 MMSE / PDD by McKhann et al., 
1984 
Camicioli et al., 2005
86
 19 28   MMSE / PDD by DSM-IV 
Jasinska-Myga et al., 
2007
87
 
100 98   MMSE, attention and working 
memory, executive, memory, 
language, visuospatial / PDD 
byICD-10 and DSM-IV 
Ezquerra et al., 2008
88
 138 86  91 NA / PDD by MDS Task Force 
Beyer et al., 2013
31
 73*  18  MMSE, executive, memory, 
visuospatial / PD-MCI if cognitive 
performance < 1.5 SDs below 
predicted level 
Feldman et al., 2006
79
 49 38   NA / DSM-IV APOEε4 associated with PDD 
Tröster et al., 2006
90
 62   146 DRS, attention and working 
memory, executive, memory, 
language 
Absence of APOEε4 associated with 
working memory impairment 
Pankratz et al., 2006
80
 274 50   PDD by MMSE with education-
specific cutoff 
APOEε4 associated with PDD 
Papapetropoulos et al., 
2007
81
 
33 39   PDD by American Psychiatric 
Association 1987,1994 or MMSE 
< 24 
APOEε4 associated with PDD 
Blazquez et al., 2006
78
 276 212   MMSE / PDD if < 24 APOEε4 associated with cognitive 
impairment in familial PD 
Mata et al., 2014
83
 1079**    MOCA, attention and working 
memory, executive, memory, 
language, visuospatial 
APOEε4 associated with ↓ memory, 
executive function, attention and 
language. 
APOE 
LONGITUDINAL 
Harhangi et al., 2000
95
 79 25  4673 PDD by DSM-III-R APOEε2 and APOE ε4 ↑ risk of PDD 
 
De Lau et al., 2005
94
 139    MMSE / PDD by DSM-III-R APOEε2 and APOE ε4 ↑ risk of PDD 
 
Kurz et al., 2009
89
 95   73 MMSE / PDD by DSM-IV APOE not associated with cognitive 
performance at baseline or annual 
decline 
Williams-Gray et al., 
2009
91
 
101    MMSE, executive, memory, 
language / PDD byMMSE ≤ 24 
and DSM-IV 
No differences 
Siderowf et al., 2010
22
 45    DRS-2 / PDD if < 124 APOEε4 not associated with 
cognitive decline 
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Abbreviations. NA, Not Available. Genes: APOE, Apolipoprotein E; MAPT, Microtubule Associated 
Protein Tau; GBA, Glucocerebrosidase. Subjects: PDND, Parkinson’s disease non-demented; PDD, 
Parkinson’s disease dementia; PD-MCI, Parkinson’s disease mild cognitive impairment; PDCN, 
Parkinson’s disease cognitively normal; C, control. Cognitive assessment: DRS, Mattis Dementia Rating 
Scale; DRS-2, Mattis Dementia Rating Scale (version 2); NINCDS, National Institute of Neurological 
Disorders and Stroke; MMSE, Mini Mental State Examination; MOCA, Montreal Cognitive Assessment; 
DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition; DSM-IV, 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; ICD-10, International Statistical 
Classification of Diseases and Related Health Problems 10th Revision; MDS, Movement Disorders Society. 
 
 
*     PD cognitively normal 
**   PD (the cognitive status is not specified) 
 
Morley et al., 2012
92
 212    DRS-2 APOEε4 associated with cognitive 
decline 
MAPT 
CROSS-SECTIONAL 
Ezquerra et al., 2008
88
 138 86  91 PDD by MDS Task Force No differences 
Mata et al., 2014
83 
1079**    MOCA, attention and working 
memory, executive, memory, 
language, visuospatial 
No association with cognitive 
performance 
Setó-Salvia et al., 
2011
96
 
2154 48  374 DRS / PDD by DSM IV-R PDD vs. C: ↑ frequency of H1. 
rs1467967-A allele and haplotype 
H2a (del-In9 variant) ↓ in PDD 
MAPT 
LONGITUDINAL 
Goris et al., 2007
98
 109**    MMSE H1/H1 ↑ cognitive decline 
Williams-Gray et al., 
2009
97
 
126    MMSE, executive, memory, 
language / PDD by MMSE ≤ 24 
and DSM-IV 
H1/H1 predictor of cognitive decline 
over 5.2 years 
Morley et al., 2012
92
 212**    DRS-2, attention, memory, 
initiation-perseveration, 
construction, and 
conceptualization 
H1/H1 associated with ↓ memory at 
baseline, but not with changes over 
time 
GBA 
CROSS-SECTIONAL 
     
Alcalay et al. 2010
107
 699    MMSE, Self-report of cognitive 
impairment 
Association with self-reported 
cognitive impairment 
Setó-Salvia et al., 
2011
96
 
225*   186 Clinical Dementia Rating Scale / 
PDD by DSM IV-R 
Association with PDD 
Alcalay et al., 2012
106
 72*    MMSE, CDR, executive, memory, 
visuospatial 
Association with ↓ memory and 
visuospatial function 
GBA 
LONGITUDINAL 
      
Winder-Rhodes et al., 
2013
109
 
121    MMSE / PDD by DSM IV Associated with progression to PDD 
Brockmann et al., 
2015
108
 
39    MOCA Associated with ↑ cognitive decline 
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Recently, a higher prevalence of dementia,
105, 106
 MCI,
106
 and poor outcomes in global 
cognition,
107
 memory and visuospatial function
106
 was observed in PD patients carrying 
GBA mutations. Moreover, GBA mutations are associated with greater cognitive 
decline
108
 and development of PDD
109
 in longitudinal studies, and with higher high LB 
burden.
110
 It has been postulated that the poorer lysosomal activity linked to GBA 
mutations could reduce the turnover of α-synuclein through chaperone mediated 
autophagy, leading to LB formation.
110
 
Genes related to defective neurotransmission relevant to cognition in PD have also been 
studied. In relation to dopamine metabolism, the Val158Met polymorphism of the 
catechol-o-methyl transferase (COMT) gene is associated with poor performance in 
executive function or attention
92, 111-115
 but apparently, not with dementia.
97
 No studies 
have assessed genes related to acetylcholine metabolism in PDD or PD-MCI patients, and 
no association between polymorphisms in the CHRNA4 gene (the nicotinic receptor 
subunit alpha-4) and cognition have been encountered in PDCN patients.
116
 Similarly, an 
association between genes related to the metabolism of homocysteine and cognition in PD 
has not been observed.
48, 51
 Conversely, polymorphisms in the IL-17A
117
 and BDNF genes 
118
 
119
 have been associated with poorer global cognition
119
 and delayed recall.
118
 
In summary, although there are contradictory results regarding the APOE ε4 allele and the 
H1 haplotype of the MAPT gene, methodological issues (i.e. differences in the size of the 
cohorts studied, the cognitive assessment and diagnostic accuracy for dementia and MCI, 
disease duration, the age of the patients, etc.) impair making comparisons between them. 
Meta-analysis of cross-sectional studies
91
 and longitudinal studies with larger cohorts
92, 94, 
95, 97
 suggest that these genetic variants can be considered risk factors for dementia in PD. 
More recently, GBA mutations emerged as the strongest genetic predictive marker of 
 23 
dementia.
105, 106, 108, 109
 These genetic variations may account for, or have a great impact 
on, the subtype of PD-MCI and the risk of dementia.  
MAGNETIC RESONANCE IMAGING (MRI) 
Gray matter changes 
Several cross-sectional studies have demonstrated higher brain atrophy in PDD and PD-
MCI patients (more extensive in PDD) than in control subjects, PDCN or PDND,
31, 120-153
 
particularly in the parietal, occipital, temporal and frontal lobes, yet also in the 
hippocampus, amygdala, caudate, putamen, thalamus and substantia innominata (Figure 
1). As expected, PDD patients had less gray matter (GM) volume than PD-MCI patients 
in several temporal and prefrontal areas,
137
 including the amygdala,
123
 and they had 
reduced cortical thickness in the anterior cingulate, entorhinal and orbitofrontal cortices, 
as well as in the parahippocampus, temporal pole, precuneus, and fusiform and lingual 
areas.
121
 Interestingly, several studies report correlations between different areas of GM 
loss and cognitive function,
31, 121, 123, 127, 131, 134, 142, 146, 150, 154-162
 although in terms of 
biomarkers of dementia and MCI, longitudinal studies are much more valuable. Thus, 
reduced cortical thickness in the right precentral and superior frontal gyri, as well as in the 
anterior cingulate cortex,
21
 and less GM volume in the prefrontal areas, insular cortex and 
caudate nucleus,
163
 along with hippocampal atrophy, were observed in PD patients who 
developed dementia during follow-up.
164
 Interestingly, hippocampal volume was also a 
major factor predicting the development of MCI in PD patients,
164
 and a sophisticated 
analysis using Bayesian network classifiers showed that PDD, PD-MCI and PDND 
patients were classified on this basis with high sensitivity and specificity.
165
 In this study, 
reduced GM in the left hippocampus and right entorhinal cortex, and enlargement of the 
lateral ventricles identified PDD patients, and brainstem and left hippocampus atrophy 
was seen in PD-MCI patients.
165
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In summary (Figure 1), although there are many studies in this field, the most valuable are 
those with larger cohorts 
31, 122, 131, 138, 142, 152, 153, 158
 and more advanced analytic 
approaches
121, 125, 148, 152, 157, 165
, especially the longitudinal studies,
21, 152, 163, 164
 
Accordingly, reduced cortical volume or thickness in several areas, and especially in the 
hippocampus,
164
 appears to be associated with progression to dementia and MCI. This is a 
promising avenue to be followed, whereby well-designed prospective studies using 
modern analytical models might help to validate these findings or identify new patterns 
that could serve as potential biomarkers. 
 
 
White matter microstructure: Diffusion Tensor Imaging 
Reduced fractional anisotropy (FA) or increased mean diffusivity (MD) in diffusion 
tensor imaging (DTI) studies can indicate alterations in the microstructure of WM tracts. 
Both approaches show that dementia and MCI in PD are associated with extensive areas 
of modified WM microstructure (Figure 1).
153, 166-172
 Reduced FA is widespread in PDD 
compared with PDND patients or controls, compromising the main tracts (the superior 
and inferior longitudinal, inferior fronto-occipital and uncinate fasciculi, the cingulum, the 
anterior limb of the internal capsule, and the hippocampus).
153, 166-170
 In PD-MCI patients, 
the superior longitudinal, inferior fronto-occipital and uncinate fasciculi, as well as the 
cingulum, corpus callosum and corona radiata had a lower FA than in PDCN or control 
subjects.
153, 166, 169, 171
 Notably, while PDD patients had reduced GM volume and FA, PD-
MCI subjects only showed FA abnormalities in the main WM tracts,
153
 suggesting that 
tract damage may precede GM atrophy. Regarding MD, results are analogous to those 
found in FA for both PD-MCI and PDD patients.
166, 168, 172
 On the other hand, both FA 
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and MD values have been correlated with cognitive outcomes,
153, 161, 167-170, 172-175
 possibly 
indicating a role in the detection of subtypes of cognitive failure associated with PD. 
Overall, the corpus callosum,
153, 171
 corona radiata,
166, 171
 and the inferior and superior 
longitudinal fasciculi are the areas most consistently altered in PDD and PD-MCI 
patients.
153, 166, 171
 The fact that in absence of GM changes, PD-MCI patients exhibited 
alterations in the main WM tracts
153
 suggests that DTI studies might help in the early 
diagnosis of cognitive decline. Longitudinal studies are not currently available and they 
will be needed to determine whether any of these changes may be considered as true 
biomarkers of MCI or dementia in PD. 
 
Functional MRI: Cerebral blood flow 
Functional MRI (fMRI) in resting state or during the execution of tasks indirectly 
measures neural activity and is used to study the regional activation of the brain and the 
association or dependency between two or more anatomic locations, termed functional 
connectivity. During the execution of working memory or executive function tasks, PD-
MCI patients more weakly recruit the anterior cingulate cortex, caudate, medial and 
dorsolateral prefrontal cortex (DLPFC), and left precentral gyrus than PDCN patients.
176-
178
 However, similar findings were observed in PDCN patients when compared with 
controls
179
 suggesting that these changes are associated with executive dysfunction in 
PD.
180, 181
 Interestingly, genetic variants in PDND patients are associated with reduced 
recruitment of specific brain areas when executing certain tasks: the MAPT H1 haplotype 
in parietal
115
 and medial temporal
99
 regions when performing visuospatial and memory 
tests;
99
 APOE ε4 allele in the temporo-parietal network in relation to memory encoding;115 
and COMT met/met homozygosity of the Val158Met polymorphism in the prefrontal 
cortices, frontoparietal network and caudate nuclei when executing frontal tasks.
111, 113, 115
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In the resting state, reduced inter-regional correlations have been encountered in PDD 
(caudate nucleus-posterior cingulate cortex/precuneus
182
 and inferior occipital-right 
parahippocampal gyri
172, 183
) and in PD-MCI (long range connections)
184, 185
 patients. In 
addition, reduced connectivity in the frontoparietal network is associated with poor 
cognitive outcome in PD-MCI,
186
 and progressive loss of functional connectivity in 
posterior parts of the brain was associated with cognitive decline in the only longitudinal 
study available.
187
 One interesting approach is to study the default network that reflects 
the predominant activity at rest, which is dampened when switching to a cognitive task. In 
PDD patients, this network has weaker connectivity in the right inferior frontal gyrus
188
 
and is less intensely deactivated than in controls when confronted with a complex visual 
task.
183
  
Considering the data available (Figure 1), it can be speculated that there are two main 
functional networks in the resting state: one more anterior one that seems to be related to 
executive dysfunction; and another more posterior one that might herald the evolution to 
dementia.
187
 Activation studies indicate that fMRI might be helpful in the diagnosis of 
PD-MCI subtypes, which may also complement studies of genetic predictive markers in 
patients. 
 
Proton magnetic resonance spectroscopy: metabolite spectra 
Proton magnetic resonance spectroscopy (PMRS) allows certain metabolites to be 
quantified in vivo, reflecting the integrity of different elements in the brain, such as N-
acetyl aspartate (NAA, neurons), choline compounds (Cho, cell membranes) and creatine 
(Cr, energy metabolism).
189
 PDD patients have less NAA
190
 and PD-MCI patients a lower 
NAA/Cr ratio
191
 than PDND patients in the occipital lobe, which correlates with poorer 
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visuospatial and working memory function.
190
 In addition, PDD
191
 and PD-MCI
189
 
patients had lower respective NAA/Cr and Cho/Cr ratios in the cingulate cortex than 
controls. Moreover, levels of NAA were reduced in the DLPFC of PD-MCI patients and 
in the hippocampus of PDD patients,
192
 and they were positively correlated with frontal 
tasks and language function,
192
 respectively. A correlation between the NAA/Cr ratio in 
the anterior cingulate cortex with short-term  memory,
193
 and with executive function and 
perception,
 194
 has also been observed. Finally, the inorganic phosphate/ATP ratio, a 
measure of oxidative metabolism, was negatively correlated with global cognition and 
language in PDND patients.
195
 Longitudinal studies are needed to decipher whether the 
biochemical alterations described might predict conversion to dementia or identify 
subtypes of PD-MCI. 
In summary, despite the number of studies undertaken with MRI, no reliable biomarker of 
dementia has been identified. From the information provided by the different MRI 
modalities in the few longitudinal studies available, the most consistent conclusion points 
to the fact that a lower hippocampal volume and dysfunction of the posterior-hippocampal 
network, witnessed either by fMRI or spectroscopy, might signal the eventual 
development of dementia. Nevertheless, their value at the individual level has to be 
further explored. 
 
PET AND SPECT IMAGING 
Dopaminergic denervation 
Several studies have identified dopaminergic deficits in the striatum, anterior cingulate 
and midbrain in PDD patients, and in the striatum and the insula of PD-MCI patients 
compared with PDCN patients.
176, 196-199
 However, in all types of patients (PDCN, PD-
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MCI and PDD) these deficits are associated with poor executive function, especially those 
in the striatum,
176, 200-206
 and less consistently with verbal and visual memory
126
 or global 
cognition.
196
 In addition, several studies failed to find an association between dopamine 
depletion and cognitive impairment.
207-209
 Therefore, the assessment of the dopaminergic 
system with these imaging techniques could serve as a biomarker of executive PD-MCI, 
an important entity with implications for functional performance. However, this does not 
seem to be sufficiently reliable to serve as a biomarker of dementia or MCI. 
 
Cholinergic denervation 
Pathological studies
210
 and pharmacological trials with acetylcholinesterase inhibitors
211 
indicate that the cholinergic disfunction is relevant in dementia in PD. Studies using 
different radiotracers (Supplementary Table 2), show that the cholinergic activity in PDD 
patients was weaker in the whole cortex,
212-214
 and in the occipital,
213
 precentral, parietal, 
temporal and posterior cingulate cortex
215
 than in PDND and healthy subjects.
216, 217 
Compared with controls, cholinergic deficits were evident in the midbrain, pons and 
cerebellum in one study of PD-MCI patients
218 
but not in another that included more 
patients.
198
 In addition, lower cortical cholinergic activity has been associated with worse 
global cognition
219, 220
 and language,
221
 and with working memory impairment in PDD 
and PDND patients.
217
 
PET studies indicate that assessing the cholinergic state might be useful as a biomarker of 
dementia in PD. Despite the evidence available, the current accessibility of the 
radiotracers precludes more extensive research and the clinical use of this technique. 
 
 29 
Supplementary table 2. Summary of PiB PET and acetylcholine-related PET and SPECT studies assessing 
PD-MCI or PDD and those reporting correlations with any cognitive measure in PD, PDND or PDCN. 
 
 AUTHOR 
AND 
YEAR 
PATIENTS COGNITIVE 
EVALUATION / 
DIAGNOSTIC 
CRITERIA 
MAIN RESULTS 
[
11
C]-PIB PET 
Amyloid load 
Maetzler et 
al., 2008
225
 
PDD (n=10) 
C (n=6) 
MMSE / PDD by DSM-IV 2/10 PDD ↑ uptake in cortical areas 
Edison et 
al., 2008
222
 
PDND 
(n=10) 
PDD (n=12) 
C (n=41) 
MMSE / PDD by MDS 
Task Force 
2/12 PDD ↑ uptake 
 
Maetzler et 
al., 2009
20
 
PDND 
(n=14) 
PDD (n=12) 
MMSE / PDD by DSM-IV 4/12 PDD ↑ uptake in the frontal, posterior cingulate, 
cuneus/precuneus, temporo-parietooccipital cortices 
and striatum  
Burack et 
al., 2010
226
 
PDD (n=3) MMSE, CDR / PDD by 
MDS Task Force 
2/3 autopsy confirmed PDD ↑ uptake in orbitofrontal, 
prefrontal cortex, precuneus and temporal lobes  
Foster et 
al., 2010
229
 
PDCN (n=8) 
PD-MCI 
(n=9) 
PDD (n=15) 
C (n=9) 
CDR, attention and 
working memory, 
executive, memory, 
language, visuospatial / 
PDD by MDS Task Force; 
PD-MCI if CDR=0.5 
No differences 
Jokinen et 
al., 2010
253
 
PDND (n=8) 
PDD (n=11) 
MMSE, attention and 
working memory, 
executive, memory / PDD 
by MDS Task Force 
 3/11 PDD and 2/24 C ↑ uptake in cortical areas 
Gomperts 
et al., 
2012
228
 
 
PDCN 
(n=29) 
PD-MCI 
(n=14) 
PDD (n=12) 
C (n=85) 
MMSE, CDR, attention 
and working memory, 
executive, memory, 
language, visuospatial / 
PDD by MDS Task Force; 
PD-MCI if one abnormal 
aggregate cognitive domain 
score -1.5 SD 
No differences 
Petrou et 
al., 2012
224
 
PDNC (n=5) 
PD-MCI 
(n=30) 
PDD (n=5) 
MOCA, attention and 
working memory, 
executive, memory, 
visuospatial / PD-MCI 
based on domain Z-scores 
(not specified) 
4/5 PDD and 2/30 PD-MCI ↑ cortical uptake. 
Negative correlation between cortical binding and 
global cognition 
Gomperts 
et al., 
2013
230
 
 
PDNC 
(n=35) 
PD-MCI 
(n=11) 
Longitudinal 
(2.5±1.4 
years follow-
up) 
MMSE, attention and 
working memory, 
executive, memory, 
language, visuospatial /PD-
MCI by Winblad et al., 
2004 
PD-MCI vs. PDCN: At baseline no differences 
Longitudinal course: Subjects progressing to a more 
severe cognitive diagnosis (n=14) ↑ baseline uptake 
Campbell 
et al., 
2013
227
 
PDD (n=53) 
C (n=67) 
MMSE, CDR / PDD by 
MDS Task Force 
PDD vs. C: No differences 
Shimada et PDD (n=7) MMSE, executive / PDD 29% of PDD ↑ uptake. No correlations between 
 30 
al., 2013
223
 C (n=17) by DSM-IV  uptake and neuropsychological tests 
Lucero et 
al., 2015
231
 
PDND 
(n=130) 
PDD (n=15) 
MMSE, CDR / PDD 
defined by CDR 
Uptake correlated with cognition in patients with <16 
years of education 
[
11
C]-PMP PET 
Acetylcholinester
ase activity 
Bohnen et 
al., 2003
216
 
PDND 
(n=11) 
PDD (n=14) 
MMSE / PDD by DSM-IV AChE activity ↓ in PDD (-20%) and in PDND (-
12.9%) vs. controls 
Bohnen et 
al., 2006
217
 
PDND 
(n=13) 
PDD (n=11) 
C (n=14) 
MMSE / PDD by DSM-IV PDD vs. C: ↓ cortical AChE activity 
PDD+PDND: Cortical AChE activity correlated with 
attention. 
Shimada et 
al., 2009
213
 
PDND 
(n=18) 
PDD (n=10) 
C (n=26) 
MMSE / PDD by DSM-IV PDD vs. PDND↓ AChE activity in the inferior tem- 
poral, supramarginal, and posterior cingulate gyri. 
 
Bohnen et 
al., 2012
219
 
PD (n=101) 
C (n=29) 
MMSE, attention and 
working memory, 
executive, memory, 
visuospatial / PDD by 
DSM-IV 
↓ cortical AChE activity, associated with ↓ in verbal 
learning, executive function, and attention 
Bohnen et 
al., 2015
220
 
PDND 
(n=143) 
MMSE, attention and 
working memory, 
executive, memory, 
visuospatial / Not reported 
↓ cortical AChE activity in PDND with worse 
cognitive outcome 
2-[
18
F]FA-85380 
PET 
α4β2* nicotinic 
acetylcholine 
receptors 
Meyer et 
al., 2009
218
 
PDCN (n=7) 
PD-MCI 
(n=8) 
C (n=9) 
MMSE, DemTecscale, 
attention and working 
memory, executive, 
memory, visuospatial / PD-
MCI defined if 
DemTecscale=8-13 
PD-MCI vs. PDCN: ↓ midbrain, pons and cerebellum 
PD-MCI vs. C: ↓midbrain, pons, left parietal cortex, 
cerebellum 
[
11
C]-MP4A 
PET 
Acetylcholinester
ase activity 
Hilker et 
al., 2005
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PDND 
(n=17) 
PDD (n=10) 
MMSE, attention and 
working memory, 
executive, memory, 
language, visuospatial / 
PDD by DSM-IV 
PDD vs. PDND: ↓ left inferior parietal lobe, left 
precentral gyrus and right posterior cingulate gyrus 
Klein et 
al., 2010
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PDND (n=8) 
PDD (n=9) 
C (n=9) 
  
[
123
I]IBVM 
SPECT 
Presynaptic 
cholinergic 
terminal density 
Kuhl et al. 
1996
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PDND (n=9) 
PDD (n=6) 
C (n=36) 
CDR / PDD by CDR 0.5 or 
clinical data 
PDD vs. PDND: ↓ extensive cortical uptake 
5-I-A-85380 
SPECT 
α4β2* 
nicotinicacetylch
olinereceptors 
Lorenz et 
al., 2014
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PD (n=25) Language Correlation between language performance and 
uptake in right superior parietal lobule, left thalamus, 
posterior subcortical region 
 
 
Abbreviations. PET/SPECT technique: PiB, Pittsburgh compound B; PMP, Methyl-piperidin-4-yl propionate; FA-85380, 3-((S)-
2-azetidinylmethoxy)pyridine; MP4A, Methylpiperidin-4-yl acetate; IBVM, Iodobenzovesamicol; A-85380, 5-iodo-3-[2(S)-
azetidinylmethoxy]pyridine. Subjects: PDND, Parkinson’s disease non-demented; PDD, Parkinson’s disease dementia; PD-MCI, 
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Parkinson’s disease mild cognitive impairment; PDCN, Parkinson’s disease cognitively normal; C, control.Cognitive assessment: 
CDR, Clinical Dementia Rating of Hughes et al., 1982; MMSE, Mini Mental State Examination; MOCA, Montreal Cognitive 
Assessment; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; MDS, Movement Disorders Society. 
 
 
Imaging amyloid 
Fibrils of Aß can be assessed in vivo by [
11
C]-Pittsburgh compound B (PiB) PET imaging. 
From the few such studies undertaken in PD patients (Supplementary Table 2), 15-80 % 
of PDD cases
20, 222-226
 and only 2 out of 30 PD-MCI patients had elevated cortical PiB 
binding.
224
 Although no differences were evident between PDD and controls
227-229
 or 
between PD-MCI and PDCN patients in several studies,
228, 229
 higher PiB retention in PD-
MCI patients predicted a greater risk of cognitive worsening.
230
 In addition, a robust 
correlation between global cognition and PiB binding was observed in PDCN, PD-MCI 
and PDD patients.
224, 231
 Therefore, while it can be argued that amyloid load might 
contribute to the development of cognitive impairment in PD,
10, 14, 232
 the in vivo results of 
PiB-PET studies are rather variable,
233
 with low sensitivity and specificity in the diagnosis 
of dementia and MCI in PD patients. Nonetheless, the paucity of studies and the 
heterogeneity in the cognitive deficits of PDD and PD-MCI patients could explain these 
inconsistent findings. As mentioned for other biomarkers related to Aß, PiB-PET might 
represent a useful biomarker for specific types of PDD with concurrent AD but not for all 
types of PDD (e.g. purer Lewy body type cases). Another factor to be considered is that 
PiB retention in PDD patients seems to be related to diffuse Aß plaques and not to mature 
plaques, which are not associated with AD but with pathological aging.
226
 
 
Imaging brain perfusion and metabolism 
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Regional cerebral blood flow (rCBF) and glucose consumption (FDG uptake - 
metabolism) can be measured by SPECT and PET respectively (Figure 2). In several 
studies PDD and PD-MCI patients exhibit areas of reduced rCBF
234-249
 and metabolism 
(more extensive in PDD),
212, 250-258
 such as in the frontal, parietal, temporal, occipital and 
cingulate cortex, the basal ganglia, thalamus and cerebellum. Interestingly, compared to 
PD-MCI, hypometabolism is more widespread in PDD patients, especially in the posterior 
cortical areas,
251
 and this heralds the progression to dementia in PD patients when 
considered in conjunction with the hypometabolism in the posterior cingulate and caudate 
nucleus.
259, 260
 Moreover, impairment in specific cognitive domains is correlated with 
patterns of rCBF and hypometabolism in several studies.
235, 251, 261-267
. Furthermore, a 
recent study in a cohort of PDD patients with a multimodal PET approach show a 
correlation between hypometabolism, amyloid load and microglial activation ([
11
C]-
(R)PK11195 PET) in the anterior and posterior cingulate, striatum and frontal, temporal, 
parietal and occipital cortical regions.
250
 
In summary, reduced rCBF and FDG uptake in the posterior cortical areas seems to be a 
useful biomarker of dementia in PD,
251
 in line with functional and spectroscopic MRI 
data.
187, 190
 In addition, considering the heterogeneity of PD-MCI, a multi-tracer approach 
might be worth studying to decipher biomarkers of MCI that could eventually develop 
into dementia. 
 
NEUROPHYSIOLOGY 
Electroencephalography (EEG) and magnetoencephalography 
PDD patients have slow EEG activity,
268-271
 with an increase in power at the delta (1-4 
Hz) and theta (4-8 Hz) frequencies.
272-274
 In addition, PD-MCI patients have increased 
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activity in the theta band in the frontal region
275
 and  reduced alpha activity (8-10 Hz) in 
the right temporal region
276
 compared with PDCN patients. Moreover, PDND patients 
with a low background rhythm frequency had a higher ratio of progression to dementia
277
 
or global cognitive decline,
278
 and low background EEG frequencies have also been 
associated with poor outcomes in global cognition,
279, 280
 attention, executive function, 
verbal fluency and long-term memory.
281, 282
 
Although expensive and with restricted accessibility, another way to measure cortical 
neuron activity is magnetoencephalography, which provides a measure of rhythmic 
activity and of the synchronization of oscillatory activity over long distances with higher 
temporal resolution. In addition to a widespread increase in the relative power of the delta 
band, and a decreased power of the alpha and beta bands,
283
 PDD patients have reduced 
long distance intra-hemispheric bilateral fronto-temporal and inter-temporal 
synchronization.
284
 As such, current evidence indicates a clear association between low 
frequency oscillatory activity and cognitive impairment. Thus, the use of novel analytical 
EEG approaches should be considered in the search for biomarkers of dementia in PD, 
particularly as they are cheap and easy to employ. 
 
Event-related potentials 
Event-related potentials (ERPs) involve cortical responses associated with sensory, motor or 
cognitive events,
285
 in which later components (after 100 ms) are thought to reflect cognitive 
processing. The most widely studied in PD is the P3 or P300 (elicited by visual or auditory 
stimuli), which appears to be delayed in PDD compared with controls
286-289
 or PDND 
patients.
290, 291
 Indeed, P300 correlates with many cognitive functions in PDND patients like 
memory, visual perception and executive functions.
292-296
 A recently developed transcranial 
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magnetic stimulation (TMS) method that is coupled to simultaneous peripheral nerve 
stimulation at different intervals can produce short latency afferent inhibition (SAI), which is 
thought to provide a measure of cholinergic function. Several studies show that SAI is 
dampened in patients with PDD
297
 and PD-MCI,
298
 while there is no difference in SAI between 
PDCN and control subjects. Due to the relevance of the cholinergic system in the cognitive 
deficits in PD, this is a promising technique to be considered in the search for biomarkers of 
PD-MCI with higher risk of dementia. 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
An important factor to consider when evaluating the potential biomarkers studied is the 
fact that dementia and MCI in PD are heterogeneous, both from the clinical and the 
pathological perspective. In addition, different biomarkers may provide complementary 
information that could be combined to achieve better sensitivity and specificity in the 
detection of dementia, and MCI with a high risk of progressing to dementia (Table 3). The 
data currently available indicate that genetic information could aid the detection of PD 
patients at a high risk of dementia at the time of diagnosis, yet this sheds no light on the 
probability and the time lag in this cognitive decline. By contrast, other biomarkers aim to 
prematurely detect dementia during the evolution of the disease and they could be 
especially useful to flag those PD-MCI patients at high risk of developing dementia in the 
short- to mid-term. 
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Table 3. Summary of the potential biomarkers of PDD and PD-MCI in function of the pathological processes implicated. 
 
BIOMARKER CSF PLASMA GENES PET/SPECT IMAGING 
 PDD PD-MCI PDD PD-MCI PDD PD-MCI PDD PD-MCI 
PATHOLOGY-RELATED    
Amyloid-ß
¥
 ↓/= ↓/= --- --- ↑ APOEε4* --- ↑PiB uptake/= ↑PiB uptake/= 
Tau
¥
 ↑/= ↑/= --- --- ↑H1 haplotype and 
H1/H1 genotype/ 
No association 
--- 
--- --- 
P-tau ↑/= ↑/= --- --- --- --- 
α-synuclein ↑/= --- --- --- Duplication, 
triplication 
--- --- --- 
NEUROTRANSMITTER DYSFUNCTION         
Dopamine --- --- --- --- = --- ↓ subcortical DaT or 
fluorodopa uptake/= 
↓ subcortical DaT 
or fluorodopa 
uptake /= 
COMT (Val158Met) associated with 
↓ executive function in PDND 
Acetilcholine --- --- --- --- --- --- ↓ cortical AChE 
activity/= 
--- 
INFLAMMATION/INMUNE RESPONSE    
CRP ↑ --- = --- --- --- 
↑ microglial 
activation in the 
cingulate, striatum, 
frontal, temporal, 
parietal and occipital 
cortices 
--- 
IL-1β --- ↑ --- --- --- --- 
IL-6
¥
 = ↑ --- --- --- --- 
IL-17A --- --- --- --- Genotype C/C of 
the rs8193036 
polymorphism;MM
SE < 26 
--- 
IL-10 --- --- --- --- Polymorphism 
RS1800896; no 
association 
--- 
TNF- α¥ = ↓ --- ---  --- 
INF-γ --- ↓ --- --- Polymorphism 
T874A; no 
association 
--- 
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PGE2 --- = --- --- --- --- 
IP10 = --- --- --- --- --- 
MIP1β = --- --- --- --- --- 
MCP1 = --- --- --- --- --- 
OXIDATIVE STRESS    
Uric acid
δ, ¥
 ↓ --- = --- --- --- --- --- 
NEUROTROPHIC/NEUROPROTECTION    
EGF
¥
 --- --- ↓ --- --- --- --- --- 
BDNF = --- --- --- PolymorphismVal1
96Met; no 
association 
--- --- --- 
Vitamin D --- --- = --- --- --- --- --- 
OTHER    
Homocysteine
¥
 ↑/= = ↑/= = Variants in MTHFR, COMT and 
other genes related to homocysteine 
metabolism; no association 
--- --- 
 
Abbreviations ”=”, No differences. Biomarkers: CRP, C reactive protein; IL-1β, Interleukin-1β; IL-6, Interleukin-6; L-17A, Interleukin 17A; IL-10, Interleukin 10; TNF-α, 
Tumor necrosis factor alpha; IFN-γ, Interferon gamma; PGE2, Prostaglandin E2; IP10, Interferon gamma-induced protein-10; MIP1β, Macrophage inflammatory protein-1; 
MCP1, Monocyte chemotactic protein-1; EGF, Epidermal Growth Factor; BDNF, Brain Derived Neurotrophic Factor; PiB, Pittsburgh Compound B. Subjects: PDND, 
Parkinson’s disease non-demented; PDD, Parkinson’s disease with dementia; PD-MCI, Parkinson’s disease with mild cognitive impairment. 
 
*APOE encodes for apolipoprotein E, and it is associated with the cerebral Amyloid-ß load 
δ
Low urine uric acid levels associated with worse performance in several cognitive outcomes  
¥
Association with cognition in PDND, PD-MCI or PDD 
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The data available allow us to conclude that genetic variants in COMT may account for 
differences in frontal dopaminergic function, they are typically associated with an executive 
subtype of PD-MCI with a low risk of dementia.
92, 97, 111-115
 By contrast, the APOE ε4 allele,92, 
94, 95
 the H1 haplotype of the MAPT gene
97, 98
 and mutations in the GBA gene
109
 all seem to be 
risk factors of dementia. However, they might be associated with different PD-MCI subtypes 
and probability of progression to dementia with slightly different cerebral pathology. Indeed, 
even in PDCN patients these mutations are associated with deficient activation in restricted 
brain territories when confronted with specific cognitive tests.
99, 111, 113, 115
 Thus, APOE ε4 
might be associated with a more amnestic AD-like phenotype of PD-MCI, while MAPT and 
GBA might be involved in more visuospatial patterns.  
Regarding the proteins related to pathological cerebral inclusions, currently only low Aß levels 
in the CSF and PiB PET studies detecting Aß fibrils in the brain could have some potential to 
detect early dementia among PD-MCI patients. This could reflect a subgroup of patients with 
concurrent AD or AD pathological changes in whom the APOE ε4 allele might be also 
overrepresented. In this sense, these markers might not be useful for the purer LB cases of 
PDD, which could in turn be more related to GBA mutations.
108-110
 Oligomers of α-synuclein in 
the CSF are worth pursuing, both in sporadic PD but importantly, also in patients with GBA 
mutations. In addition, the ratios of tau, Aß and α-synuclein could improve the predictive value 
of each protein independently, or help to differentiate between different forms of PD-MCI. 
New PET radiotracers to reliable mark in vivo tau and α-synuclein are needed to derive a 
complete picture of the clinical and pathological phenotypes of MCI subtypes, and how they 
progress towards dementia.  
In addition, independently of the genetic fingerprint and pathological cerebral inclusions, it 
may be worth pursuing the study of lipids and of proteins related to metabolic processes 
(inflammation, oxidative stress, etc.) in CSF or plasma/serum, as well as neurotrophic factors 
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putatively involved in neurodegeneration such as EGF, ILGF, UA, neurofilament light chain 
protein and fatty acid binding-protein.
47, 59, 63-65
. Besides their diagnostic value, these fluid 
biomarkers may be particularly relevant in revealing dysfunctional biological processes that 
might be targets for pharmacological modulation (e.g. inflammation).  
On the other hand, the cerebral cholinergic deficits detected by PET also seem to be a 
promising biomarker of dementia
212-215, 219, 220
 but due to practical issues, alternative cheap and 
easy ways to evaluate cholinergic function should be considered, such as new 
neurophysiological studies (TMS combined with ERP).
297, 298
 
Pathological inclusions and neurotransmission deficits provoke neuronal dysfunction and death, 
which can be assessed by structural and functional imaging. Despite the fact that atrophy in 
structures like the hippocampus
21, 163, 164
 and reduced activity/metabolism in posterior cerebral 
areas
187,  251, 
 are associated with progression to dementia, no MRI modalities or FDG-PET are 
sufficiently reliable as to accurately predict progression to dementia at the single-patient level, 
as seen in CSF and peripheral fluid studies. Similarly to what has been discussed for other 
biomarkers, it could be that these findings are associated with subtypes of MCI (ie. 
hippocampal atrophy with AD/amnestic type, and posterior dysfunction with visuospatial/LB 
type).  The coupling of different PET studies, multimodal MRI and classic and modern 
neurophysiological approaches (EEG and ERP), to more sophisticated analytical methods (i.e. 
neuronal networks, classifiers, etc.) represents a promising approach that might give rise to new 
tools to identify and stratify patients with distinct types of cognitive impairment and risk of 
dementia. 
Multidisciplinary prospective studies in large cohorts of properly classified PD-MCI patients 
that assess the most promising biomarkers encountered in PDD patients, are now necessary to 
diagnose PD-MCI patients that are at high risk of progressing to dementia. In addition, studies 
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in early PD patients could also allow subtypes of PD with precocious development of dementia 
to be identified. 
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Table 1. Summary of the studies that evaluated CSF amyloid ß1-42 (Aß1-42), total tau (t-tau), 
phosphorylated tau (p-tau), total α-synuclein (t-α-syn), and oligomeric α-synuclein (o-α-syn) as 
potential biomarkers for PDD or PD-MCI 
Table 2. Summary of genetic studies assessing APOE, MAPT and GBA as potential 
biomarkers of PD-MCI and PDD. 
Table 3. Summary of the potential biomarkers of PDD and PD-MCI in function of the 
pathological processes implicated. 
Figure 1. Summary of the potential biomarkers of PDD and PD-MCI found in studies of MRI, 
PET (cerebral metabolism) and SPECT (regional cerebral blood flow), body fluids, genetic 
background, and neurophysiology. 
Figure 2. Summary of PET and SPECT studies that have assessed cerebral metabolism or 
regional cerebral blood flow respectively as potential biomarkers of PD-MCI and PDD. 
Supplementary table 1. Summary of studies assessing CSF potential biomarkers for PDD and 
PD-MCI other than neuropathologic proteins and studies assessing potential biomarkers in 
plasma/serum and urine. 
Supplementary table 2. Summary of PiB PET and acetylcholine-related PET and SPECT 
studies assessing PD-MCI or PDD and those reporting correlations with any cognitive measure 
in PD, PDND or PDCN. 
 
